Werewolf Therapeutics, Inc. — Investor Relations & Filings
Werewolf Therapeutics, Inc. is a biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company utilizes its proprietary PREDATOR® protein engineering platform to create a novel class of conditionally activated proinflammatory immune modulators, known as INDUKINE™ and INDUCER™ molecules. These therapies are designed to be delivered systemically in an inactive state and become selectively activated within the tumor microenvironment. This approach aims to generate a potent, localized anti-tumor immune response while minimizing the systemic side effects associated with conventional immunotherapies. The company's pipeline includes clinical-stage candidates such as WTX-124 and WTX-330.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | |
| 8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | |
| 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-24 | English | |
| 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-13 | English | |
| SCHEDULE 13G/A Filing | 2026-02-11 | English | |
| 8-K Filing | 2026-02-06 | English |
Browse filings by year
8 years| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 33058433 | 10-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | ||
| 33058414 | 8-K - Werewolf Therapeutics, Inc. (0001785530) (Filer) | 2026-03-27 | English | ||
| 32898233 | 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-24 | English | ||
| 32898234 | 8-K - WEREWOLF THERAPEUTICS, INC. (0001785530) (Filer) | 2026-02-13 | English | ||
| 31705258 | SCHEDULE 13G/A Filing | 2026-02-11 | English | ||
| 31705271 | 8-K Filing | 2026-02-06 | English | ||
| 13198047 | Director's Dealing 2026 | 2026-01-20 | English | ||
| 13198048 | Major Shareholding Notification 2026 | 2026-01-16 | English | ||
| 13198049 | Director's Dealing 2026 | 2026-01-15 | English | ||
| 13198050 | Director's Dealing 2026 | 2026-01-12 | English | ||
| 13198051 | Director's Dealing 2026 | 2026-01-07 | English | ||
| 13198052 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198053 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198054 | Regulatory Filings 2026 | 2026-01-06 | English | ||
| 13198055 | Regulatory Filings 2026 | 2026-01-06 | English | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
BIOMARIN PHARMACEUTICAL INC
A global biotechnology company developing therapies for rar…
|
BMRN | US | Manufacturing |
|
BioMaxima S.A.
Manufacturer and distributor of in-vitro diagnostics for cl…
|
BMX | PL | Manufacturing |
|
Biomea Fusion, Inc.
A clinical-stage biopharma developing oral drugs for diabet…
|
BMEA | US | Manufacturing |
|
BIOME AUSTRALIA LIMITED
Develops and distributes evidence-based probiotics and comp…
|
BIO | AU | Manufacturing |
|
Biome Grow Inc.
Production and distribution of cannabis products focused on…
|
BIO | CA | Manufacturing |
|
BIOMERICA INC
Develops in-vitro diagnostic and therapeutic products for c…
|
BMRA | US | Manufacturing |
|
bioMérieux
A global leader in in vitro diagnostics for clinical and in…
|
BIM | FR | Manufacturing |
|
BIOMM SA
Develops and manufactures biopharmaceuticals and biosimilar…
|
— | BR | Manufacturing |
|
BiomX Inc.
Clinical-stage company developing phage therapies to target…
|
PHGE | US | Manufacturing |
|
BIONEERCORPORATION
Develops and manufactures molecular biology products for re…
|
064550 | KR | Manufacturing |
Werewolf Therapeutics, Inc. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/34192/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=34192 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=34192 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=34192 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 34192}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Werewolf Therapeutics, Inc. (id: 34192)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.